<DOC>
	<DOCNO>NCT02783222</DOCNO>
	<brief_summary>This randomize study evaluate efficacy impact function two different dos nab-Paclitaxel elderly patient advance breast cancer .</brief_summary>
	<brief_title>EFficacy Impact Function Two Different Doses Nab-paclitaxEl Elderly With advanCed breasT Cancer</brief_title>
	<detailed_description>This open-label , randomized phase II trial evaluate parallel two dos nab-Paclitaxel ( 100 125mg/m2 ) give weekly 3 week every 28 day , elderly woman age 65 year old , first line treatment advance breast cancer ( locally recurrent metastatic ) . A short geriatric evaluation co-morbidity functional status perform study entry . The functional status monitor baseline every cycle treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically cytologically confirm breast cancer , locally recurrent and/or metastatic ; estrogen/progesterone receptor status ; HER2 receptor negative OR HER2 positive contraindication antiHER2 therapy ( e.g . know congestive cardiac failure ) . Measurable disease nonmeasurable evaluable disease accord RECIST 1.1 criterion ECOG performance status 02 Estimated life expectancy ≥ 12 week No know active/symptomatic CNS metastases No previous chemotherapy breast cancer advance set Adequate organ function include ( Hemoglobin ≥ 9g/dL ; Absolute neutrophil count ≥ 1.5 x 10^9/L ; Platelets ≥ 100 x 10^9/L ; Bilirubin ≤ 1.5 mg/dL ; ALT AST ≤ 3 x ULN ( without know hepatic metastasis ) ; ALP ≤ 2.5 x ULN ; Serum creatinine ≤ 1.5 ULN calculate creatinine clearance ( CrCl ) ≥ 50mL/min accord Cockcroft Gault formula Written inform consent ( accord ICH/GCP national/local regulation ) Significant peripheral neuropathy ( significant peripheral neuropathy define ≥ grade 2 CTCAE v4.0 criterion ) Clinically significant comorbidities include : uncontrolled cardiac arrhythmia ( except ratecontrolled atrial fibrillation ) , NYHA class III IV cardiac failure , uncontrolled diabetes , hypertension medical condition may interfere assessment toxicity Other malignancy within last 5 year , except adequately treat nonmelanomatous skin cancer , cervical intraepithelial neoplasia cervical carcinoma situ Intake concomitant medication therapy may potentially interact trial agent . Any prohibited medication must discontinue least 14 day prior trial entry Presence psychological , familial , sociological geographical condition may potentially hamper compliance study protocol followup schedule ; condition discuss patient trial registration</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>elderly patient</keyword>
</DOC>